Trevi Therapeutics, Inc. reports news on its clinical-stage biopharmaceutical development of Haduvio, an oral extended-release formulation of nalbuphine, for chronic cough in patients with idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough. Company updates commonly cover clinical trial results and plans, FDA interactions, medical-conference presentations, intellectual property, and the investigational status of Haduvio.
Trevi also reports financing and corporate updates tied to its development strategy, including common stock offerings, quarterly financial results, cash runway commentary, and participation in healthcare investor events.
Trevi Therapeutics (TRVI) reported a third-quarter 2026 net loss of $21.5 million while advancing its chronic cough trials. The loss widened from $11.8 million a year earlier. Cash, cash equivalents and marketable securities totaled $299.4 million; Trevi expects funding into 2030, including through potential FDA approval for Haduvio in idiopathic pulmonary fibrosis (IPF)-related chronic cough.
Both Phase 3 OCEAN trials are recruiting. Trevi expects OCEAN-2 results in the second half of 2027 and OCEAN-1 results in the first half of 2028. Following FDA alignment on development, Trevi expects to start a Phase 2 trial for non-IPF interstitial lung disease-related cough in the first quarter of 2027, subject to FDA protocol review. Phase 2b LAKE results remain expected in the second half of 2027. A patent application covering dosing in hepatically impaired non-IPF patients received a Notice of Allowance; once issued, expiry is expected in 2041.
Trevi Therapeutics (Nasdaq: TRVI) will review third-quarter 2026 financial results and provide a corporate update on November 9, 2026. Senior management will host a conference call and live audio webcast at 4:30 p.m. ET covering the quarter ended September 30, 2026. An archived webcast replay will remain available on the company’s website for 30 days after the event.
Trevi Therapeutics (Nasdaq: TRVI) will participate in a fireside chat at the Stifel 2026 Healthcare Conference on November 11, 2026.
The chat is scheduled for 10:00 a.m. ET with President and Chief Executive Officer Jennifer Good and Chief Financial Officer David Hastings. Both executives will also hold investor meetings with attendees. The conference runs November 10–12 in New York.
Trevi Therapeutics (TRVI) announced acceptance of Phase 2b CORAL trial results for an oral presentation at the CHEST 2026 Annual Meeting.
Philip Molyneaux will present patient-reported outcomes for nalbuphine extended-release in patients with idiopathic pulmonary fibrosis and chronic cough on October 20, 2026, from 1:45–2:30 p.m. MST. The meeting runs October 18–21 in Phoenix, Arizona.
Trevi Therapeutics (TRVI) will participate in several healthcare and investor conferences in September 2026, featuring fireside chats and panel discussions in New York and Boston.
Events include the Cantor Global Healthcare Conference, H.C. Wainwright and Morgan Stanley healthcare conferences, and the 10th Anniversary IPF Summit, with company executives presenting and joining panels on IPF trials and development strategy.
Trevi Therapeutics (Nasdaq: TRVI) will present two abstracts on oral nalbuphine extended-release (ER) for chronic cough at the European Respiratory Society (ERS) Congress 2026 in Barcelona, Spain, from September 5-9, 2026.
One oral presentation will cover quality-of-life outcomes from the Phase 2b CORAL trial in idiopathic pulmonary fibrosis (IPF)-related chronic cough, and one poster will address quality-of-life outcomes from the Phase 2a RIVER trial in refractory chronic cough (RCC), both using the Leicester Cough Questionnaire (LCQ).
Trevi Therapeutics (Nasdaq: TRVI) reported second quarter 2026 results and advanced multiple trials of its investigational chronic cough therapy Haduvio (oral nalbuphine ER). The company initiated the Phase 3 OCEAN-1 trial in IPF-related chronic cough and the Phase 2b LAKE trial in refractory chronic cough in the second quarter. OCEAN-2, a second Phase 3 IPF-related chronic cough trial, is expected to start in the third quarter of 2026.
Trevi ended the quarter with $318.9 million in cash, cash equivalents and marketable securities, boosted by an April 2026 equity offering that generated $162.3 million in net proceeds. R&D expenses rose to $15.2 million and G&A to $5.4 million, driving a net loss of $17.8 million. The company expects its current cash to fund operations into 2030, including Haduvio development in IPF-related chronic cough through potential FDA approval and Phase 3 development for non-IPF ILD-related chronic cough.
Trevi Therapeutics (Nasdaq: TRVI) announced that senior management will host a conference call and live audio webcast on Thursday, August 6, 2026, at 4:30 p.m. ET. The event will provide a corporate update and review Trevi’s second quarter 2026 financial results for the period ended June 30, 2026.
Trevi is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral nalbuphine ER) for chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). According to the company, registration and access details are available in the Investors & News section of its website, with a webcast replay accessible for 30 days.
Trevi Therapeutics (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing its investigational therapy Haduvio (oral nalbuphine ER) for chronic cough in IPF, non-IPF ILD, and refractory chronic cough, will participate in two August 2026 biotech conferences: Oppenheimer's Biotech in the Berkshires on August 4 in Massachusetts and Stifel's 2026 Biotech Summer Summit on August 10-12 in Newport, Rhode Island, including an in-person fireside chat on August 10, 2:00–2:20 p.m. ET.
Trevi Therapeutics (Nasdaq: TRVI), a clinical-stage biopharma developing investigational therapy Haduvio (oral nalbuphine ER) for chronic cough in IPF, non-IPF ILD, and RCC, announced its June–July 2026 event schedule.
Senior leaders will attend BIO International, Leerink Partners Therapeutics Forum, and ERS Cough Conference.